Tumor immunotherapy with alternative reading frame peptide antigens

Area of Science:

• Molecular Biology
• Immunology
• Oncology

Background:

• Eukaryotic translation machinery can produce errors, leading to alternative reading frame (Arf) polypeptides.
• These aberrant polypeptides can arise from tumor-associated antigens (Ag), such as HER-2, TERT, and PAP.
• Investigating Arf products offers a potential avenue for cancer immunotherapy.

Purpose of the Study:

• To predict and evaluate alternative reading frame (Arf) polypeptides derived from tumor-associated antigens (Ag).
• To assess the immunoprotective potential of Arf peptides in a preclinical cancer model.
• To explore the development of novel vaccines for antigen-specific cancer immunotherapy.

Main Methods:

• Prediction of Arf polypeptides from the cDNA of HER-2, TERT, and PAP tumor-associated antigens.
• Immunization of mice using Arf peptide-pulsed antigen-presenting cells (APC).
• Assessment of in vivo immune protection against tumors expressing the respective tumor-associated Ag.
• Characterization of CD8+ T cell responses against HER-2 transfected tumor cells.

Main Results:

• Immunization with Arf peptide-pulsed APCs induced potent in vivo immune protection against tumors expressing corresponding tumor-associated Ag.
• CD8+ T cells from mice immunized with HER-2 derived Arf peptides specifically recognized HER-2 transfected tumor cells.
• The study demonstrates the immunogenicity of Arf peptides derived from tumor-associated antigens.

Conclusions:

• Alternative reading frame (Arf) polypeptides from tumor-associated antigens can elicit protective anti-tumor immunity.
• Arf peptides represent promising targets for the development of novel cancer vaccines.
• This strategy holds potential for Ag-specific immunotherapy of human malignancies.